VivoSeq
Other

Salmeterol

0

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Salmeterol is an early-stage landscape with 0 programs across 8 companies. The most active players are Respirent Pharmaceuticals Co Ltd., Boehringer Ingelheim, GSK.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Respirent Pharmaceuticals Co Ltd.

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalOrion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

0 programs

PreclinicalChiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

60

clinical trials

Completed47 · 78%
Unknown status6 · 10%
Terminated3 · 5%
Withdrawn3 · 5%
Recruiting1 · 2%

Clinical Trials

Trial Activity

60 trials

Salmeterol Effect on Exercise Performance
Recruiting·UUniversity of Copenhagen·N/A·NCT06655012·36 enrolled
A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Completed·RRespirent Pharmaceuticals Co Ltd.·Phase 1·NCT03820180·34 enrolled
A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/Salmeterol
Completed·GSK logoGSK·Phase 1·NCT01540708·36 enrolled
Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment
Completed·NNeutec Ar-Ge San ve Tic A.Ş·Phase 4·NCT03395002·58 enrolled
Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)
Completed·GSK logoGSK·N/A·NCT01332409·2,000 enrolled
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus
Completed·Orion Corporation, Orion Pharma logoOrion Corporation, Orion Pharma·Phase 1·NCT02162485·129 enrolled
The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD
Completed·QQueen's University·N/A·NCT00559312·18 enrolled
Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort
Completed·Novartis logoNovartis·Phase 4·NCT02516592·500 enrolled
Pharmacological Properties of Salmeterol
Completed·UUniversity of Copenhagen·Phase 4·NCT02558088·11 enrolled
Generation of Biological Samples Positive to Salmeterol for Anti-Doping Control
Completed·PParc de Salut Mar·Phase 1·NCT04195867·4 enrolled
EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI
Completed·Chiesi Farmaceutici S.p.A. logoChiesi Farmaceutici S.p.A.·Phase 3·NCT00394368·180 enrolled
Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
Completed·GSK logoGSK·N/A·NCT01395862·1,001 enrolled
The Effect of Salmeterol on Eosinophil (EOS) Function
Completed·UUniversity of Wisconsin, Madison·N/A·NCT00214019·36 enrolled
Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT02254174·36 enrolled
Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 4·NCT00530842·344 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)